Anti-PD1 armored CD19 CAR-T cells therapy (Topcel-KH Pharmaceutical)

N/A

Report date: 2026/01/28 20:01:42

Base Information

Drug NameAnti-PD1 armored CD19 CAR-T cells therapy (Topcel-KH Pharmaceutical)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT lymphocyte replacementsB-lymphocyte antigen CD19 modulatorsAnti-PD-1
TargetsB-lymphocyte antigen CD19Programmed cell death protein 1
Therapy Area/IndicationsLymphoma, Large B-Cell, Diffuse
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesJiangsu Topcel-KH Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesJiangsu Topcel-KH Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsLymphoma, Large B-Cell, Diffuse
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A